HC Wainwright & Co. Reiterates Buy on Larimar Therapeutics, Maintains $15 Price Target

-2.88% Pre

LARIMAR THERAPEUTICS INC

LRMR

0.00

HC Wainwright & Co. analyst Edward White reiterates Larimar Therapeutics (NASDAQ: LRMR) with a Buy and maintains $15 price target.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Stocks slide to start week as traders brace for Nvidia earnings, jobs data

Concerns Over AI Bubble Loom! Can NVIDIA's Q3 Earnings Dispel Doubts? Citi Urges: Buy!

Will Twilio’s (TWLO) AI-Powered Expansion Redefine Its Competitive Edge in Customer Engagement?

Virginia National Bankshares CFO Tara Y. Harrison Retiring, Cathy W. Liles Names Successor, Effective Nov. 21

DeFi Development Corp. Files Form 10-Q; Says 'The Company Reported A Gain From Changes In Fair Value Of Digital Assets Of $74M For The Quarter And $96M YTD'

Barclays Maintains Overweight on Trip.com Group, Raises Price Target to $90

Highway Strengthens McLeod Software Integration to Include Real-Time Tracking and Shipment Visibility

Is Cummins Still a Bargain After 33.7% Share Price Surge in 2025?